Create Profile

Creating your profile will enable you to submit photos and stories to get published on News24.

Please provide a username for your profile page:

This username must be unique, cannot be edited and will be used in the URL to your profile page across the entire 24.com network.

Facebook Sign-In

Hi News addict,

Join the News24 Community to be involved in breaking the news.

Log in with Facebook to comment and personalise news, weather and listings.


Drugs for Ebola: A factfile

27 August 2014, 11:45

Paris -Following is a factfile on the main drugs to tackle the Ebola virus, which has claimed more than 1,400 lives in five African countries since December.

TREATMENT: No licensed drug exists for treating Ebola. Several prototypes are in the pipeline, one of which has been fast-tracked for use in the outbreak, although whether it works is unknown.

According to University of Oxford epidemiologist Oliver Brady, up to 30,000 people would have required drugs, either to combat or prevent infection, as of August 20.

ZMapp: a cocktail of three antibodies that cling to the virus and inhibit its reproduction, developed by Mapp Biopharmaceutical Inc. of San Diego, California, partly in conjunction with the US Army.

It has been tested successfully on lab monkeys but not evaluated on humans.

After the World Health Organisation said on August 12 it was ethical to use experimental treatment in the crisis, ZMapp was given to seven infected frontline workers.

Of these, two American doctors have recovered; a Liberian doctor and a Spanish priest have died; and a doctor and a nurse, both Liberian, and a British nurse, who has been flown to London from Sierra Leone, are still in treatment.

Stocks of ZMapp, which is derived from tobacco leaves and is hard to produce on a large scale, are exhausted, the company said on August 12. It is likely to take several more months "to get even a modest amount," according to Anthony Fauci, director of the US National Institute for Allergy and Infectious Diseases (NIAID).

TKM-Ebola: Drug under development by Tekmira Pharmaceuticals Corp. of Vancouver, Canada, under a $140-million (105-million-euro) contract with the Pentagon.

The drug, using a technique called RNA interference, is designed to throw a genetic switch causing the death of cells infected by the virus.

Tests on a small group of monkeys have shown it provides 100 percent protection against an otherwise lethal dose of the virus.

It is currently in a Phase I trial, the first step in the three-phase test process. In this phase, a drug is evaluated on healthy non-infected humans to see whether it is safe. Further phases test it for safety and effectiveness.

Tekmira said on August 14 that it was in contact with government agencies, NGOs and the WHO "on the potential use" of TKM-Ebola in west Africa.

Anti-viral drugs: Several proposed treatments for mitigating Ebola started out as drugs to inhibit replication of the influenza virus.

They include Avigan, a Japanese anti-flu tablet drug developed by Fujifilm Holdings Corp. that was approved in Japan on March 24 and is currently undergoing clinical trials in the United States. Japan said on August 25 it is ready to ship the drug to Ebola-hit areas if the WHO requests.

But it is unclear whether Avigan -- lab name T-705 -- will work on Ebola, which is part of a different viral family called filoviruses. No tests of T-705 have been done on Ebola-infected lab animals or humans.

VACCINES: There are two main candidates, but both face extensive trials and neither is likely to be available before 2015 even if they are fast-tracked.

The British company GlaxoSmithKline (GSK) says a prototype vaccine may enter Phase I clinical trials among a small group of human volunteers "later this year." The formula comprises an adenovirus -- a virus group best known for causing the common cold -- into which two Ebola genes have been slotted.

The virus penetrates a cell and delivers its payload, which produces a protein that triggers an immune response to recognise and destroy an invading virus.

The adenovirus is designed not to replicate further, thus preventing any spread of the Ebola genes.

The other is a vaccine by Johnson & Johnson subsidiary Crucell, designed to combat Ebola and its cousin filovirus the Marburg virus.

Tests on monkeys found the formula to be completely protective in a single dose.

A Phase I trial, launched in 2006 with 32 volunteers, found the drug was safe. Another Phase I trial, with the drug tweaked to widen protection against the spectrum of viral strains, is planned for late 2015 or early 2016.






AFP news reports and interviews



Read News24’s Comments Policy

Comment on this story
Comments have been closed for this article.

Read more from our Users

Submitted by
William Korir
CORD to stop Jubilee efforts to r...

The CORD Coalition will not allow plans to remove Kenya from the Rome Statutes take place, it has said. Read more...

Submitted by
William Korir
How long will it take Kenya to le...

Kenya is looking to leave the ICC. But what is the process behind the exit? Read more...

Submitted by
William Korir
Jubilee resumes efforts to push K...

Kenya will this week resume efforts to leave the ICC court. Read more...

Submitted by
S Mbinya
How to treat him right

Men want to go home to a woman who makes them feel loved and appreciated. Here's how to make him feel special here: Read more...

Submitted by
S Mbinya
Kenyans demand action after femal...

This comes a few days after a female passenger was drugged and then robbed in a matatu plying the Kenyatta – Kencom route. Read more...

Submitted by
S Mbinya
Natural aphrodisiacs to boost lib...

It is advisable to take them before sex in order to achieve maximum benefit. Read more...